Arch Biopartners Appoints Dr. Patrick Vink as Chairman of the Board

Arch Biopartners Inc. appointed Dr. Patrick Vink, M.D., M.B.A., as Chairman of the Board effective January 15, 2026.12

Dr. Vink has advised the pharmaceutical industry since 2015, served on boards in North America and Europe, and held senior roles at Cubist Pharmaceuticals (acquired by Merck for $9.5B in 2015), Mylan, Novartis, Biogen, and Sanofi.12

He previously served as a director of Arch Biopartners from 2016-2019 and as a Strategic Advisor thereafter.12

The appointment follows the retirement of Claude Allary, who served since 2014 and supported the company's evolution into a leading kidney therapeutics firm with two Phase II trials for acute kidney injury drugs (LSALT peptide and cilastatin).12

CEO Richard Muruvé stated Dr. Vink's pharma experience and financial network will aid Phase II AKI trials and CKD program.23

Sources:

1. https://www.marketscreener.com/news/arch-biopartners-inc-announces-appointment-of-patrick-vink-as-chairman-of-the-board-and-retirement-ce7e58ded08bf422

2. https://archbiopartners.com/2026/01/16/arch-biopartners-announces-appointment-of-dr-patrick-vink-as-chairman-of-the-board/

3. https://biotuesdays.com/2026/01/16/arch-names-dr-patrick-vink-as-chairman-of-bod/